Today: 7 February 2026
Subscribe
Browse Category

Healthcare Innovation News 4 November 2025 - 13 January 2026

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration’s request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy. (Reuters) The request matters because safety language on labels can influence how quickly doctors prescribe and how confident insurers feel about coverage. In a market already clogged with supply and demand chatter, even minor shifts in perceived risk
13 January 2026
····
Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

New York, Jan 7, 2026, 14:25 EST — Regular session Johnson & Johnson shares rose 0.9% to $206.62 on Wednesday, after the healthcare company said it filed its OTTAVA robotic surgical system with U.S. regulators. The stock traded between $204.62 and $208.25. The filing puts fresh attention on J&J’s MedTech push, a part of the business investors want to see grow as hospitals spend on new tools and procedures. A credible path to market for a surgical robot would also set up a direct fight in a field dominated by Intuitive Surgical. It lands at a busy moment for the
7 January 2026
·····
4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst

4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst

Sydney, Jan 7, 2026, 17:44 AEDT — Market closed Shares of 4DMedical Ltd (ASX:4DX) climbed 11.9% to close at A$4.69 on Wednesday after the firm said UC San Diego Health had adopted its CT:VQ lung imaging software for clinical use. About 12.8 million shares traded, MarketScreener data showed. MarketScreener+1 The contract adds a fourth U.S. academic medical centre — a university-linked teaching hospital — to deploy CT:VQ since the product won U.S. Food and Drug Administration clearance in August, sharpening investor focus on commercial traction. UCSD will use introductory pricing through March 31 before moving to full commercial terms, the
7 January 2026
····
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
·····
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors are now asking a simple question: is this the start of a longer rerating, or just another spike in a highly volatile microcap? Picard Medical Stock at a Glance (as of December 4, 2025) On December 4, 2025, Picard Medical shares closed at $3.69, up $1.67 (+82.67%) from the prior close of $2.02, making PMI one of the top gainers
5 December 2025
·····
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat+1 Behind this violent move are two concrete catalysts: At the same time, quantitative services and technical models are sending mixed—and often cautious—signals, with several “Strong Sell” ratings even as momentum screens flash “Buy” or “Strong Buy.” TipRanks+4Danelfin AI+4TradingView+4 This article walks
4 December 2025
·····
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

On December 2, 2025, Polyrizon Ltd. (NASDAQ: PLRZ) went from obscure micro-cap to center stage as its stock exploded more than 130% in a single session after the company announced a key manufacturing milestone for its flagship nasal spray platform.MarketScreener+1 The move capped one of the wildest trading days the stock has seen since its 2024 IPO: shares closed around $7.33, up 131.96% on the day, with intraday prices swinging between $5.85 and $8.36 and volume surging past 148 million shares.StockAnalysis Other outlets tracking real‑time tape during the session quoted gains ranging from roughly 80% to 142%, depending on the
2 December 2025
····
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock.The Motley Fool+1 Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and how Wall Street now frames the 2026 outlook. AbbVie stock today: price, performance and valuation As of the December 1, 2025 close, AbbVie shares trade at around $225 per share, giving the company a market capitalization near $400 billion.StockAnalysis+1 Key snapshot
1 December 2025
·····
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Published: November 18, 2025 Medtronic plc (NYSE: MDT) is back in the spotlight today after reporting stronger‑than‑expected results for the second quarter of fiscal 2026 and raising its full‑year outlook. The medical technology giant delivered solid revenue and earnings growth, highlighted powerful momentum in its cardiac ablation franchise, and signaled confidence in accelerating growth in the second half of the year. Medtronic News+1 Shares of Medtronic jumped intraday to around $100–101, up roughly 4–5% after the announcement, as investors reacted to a classic “beat‑and‑raise” quarter. ChartMill Q2 FY26 by the numbers: solid beat on revenue and EPS For the quarter
18 November 2025
····
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Key points at a glance Deal terms: a rich premium for a single late‑stage asset Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price
14 November 2025
···
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health, Inc. (NYSE: OSCR) announced new individual-market plans for South Florida ahead of the 2026 Open Enrollment window and spotlighted HelloMeno, a menopause-focused offering it and partner Elektra Health describe as the first plan of its kind in the individual market. The rollout lands as Washington headlines around ACA premium tax credits pressure managed-care shares broadly; investors are watching OSCR’s intraday action closely. Business Wire+2PR Newswire+2 Key takeaways What Oscar announced today Oscar said it will offer new, affordable individual‑market plans across South Florida for plan year 2026, with options available in Miami‑Dade, Broward, Palm Beach, Martin, and St.
10 November 2025
···
Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Company Overview: Telehealth for High-Acuity Care VSee Health, Inc. is a Silicon Valley-founded telehealth technology and services provider specializing in high-acuity virtual care. Founded in 2008 by Dr. Milton Chen, VSee built a secure video telemedicine platform so robust it was even utilized by NASA for astronaut healthcarebusinesswire.com. Today, after merging with iDoc Telehealth via a SPAC deal in mid-2024, VSee offers an integrated suite of telehealth solutions for hospitals and health systems. The company’s headquarters are in Massachusetts, and it has ~154 employees as of 2025finviz.com. Business Model: VSee’s platform combines telehealth software with physician services to enable things
4 November 2025
·
1 2

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
Go toTop